1. FDA Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs. Accessed at: www.fda.gov/Drugs/DrugSafety/ucm293101.htm . Posted Feb 28, 2012.
2. FDA Consumer Alert: Statins and HIV or Hepatitis C Drugs: drug safety communication—interaction increases risk of muscle injury. Accessed at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm294294.htm , Posted March 1, 2012.
3. FDA Consumer Alert: Important information about interactions between certain hepatitis C drugs and cholesterol-lowering statin drugs. Accessed at: http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/ucm294485.htm . Posted March 2, 2012.
4. Rzouq FS, Volk ML, Hatoum HH, et al. Hepatotoxicity fears contribute to underutilization of statin medications by primary care physicians. Am J Med Sci. 2010;340:89–93.
5. Bergmann OM, Kristjansson G, Jonasson JG, Bjornsson ES. Jaundice due to suspected statin hepatotoxicity: a case series. Dig Dis Sci. (Epub ahead of print). doi: 10.1007/s10620-011-1950-1 .